ALP Bio

ALP Bio AG is a Swiss biotech startup developing a platform that integrates human immune organoid biology with generative AI. Their goal is to help antibody developers identify, understand, and reduce immunogenicity risk earlier in the drug development process. The platform leverages human tonsil organoid technology to model immune activity in vitro and employs AI models to learn from biological datasets. This hybrid approach aims to provide more clinically relevant signals for earlier decision-making in antibody development, supporting lead candidate screening, ADA risk stratification, and sequence optimization.